[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640606":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":36,"centralContacts":49,"locations":55,"responsibleParty":71,"collaborators":36,"id":73,"slug":36,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":36,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":97,"whyStopped":36,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"InventisBio Co., Ltd","INDUSTRY",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"D-2570 9 mg (experimental arm 1)","EXPERIMENTAL","Subjects in this arm will receive oral D-2570 9 mg once daily (QD) for 24 weeks during the double-blind treatment period. Eligible subjects may continue the same dose of D-2570 9 mg in the subsequent 24-week extension period.",[13],"Drug: D-2570 9mg",{"label":15,"type":10,"description":16,"interventionNames":17},"D-2570 18 mg (experimental arm 2)","Subjects in this arm will receive oral D-2570 18 mg once daily (QD) for 24 weeks during the double-blind treatment period. Eligible subjects may continue the same dose of D-2570 18 mg in the subsequent 24-week extension period",[18],"Drug: D-2570 18mg",{"label":20,"type":10,"description":21,"interventionNames":22},"D-2570 27 mg (experimental arm 3)","Subjects in this arm will receive oral D-2570 27 mg once daily (QD) for 24 weeks during the double-blind treatment period. After 24 weeks, subjects will be re-randomized to either D-2570 9 mg or 18 mg once daily for the extension period.",[23],"Drug: D-2570 27mg",{"label":25,"type":26,"description":27,"interventionNames":28},"placebo","PLACEBO_COMPARATOR","Subjects in this arm will receive matching placebo once daily (QD) for 24 weeks during the double-blind treatment period. After 24 weeks, subjects will be re-randomized to either D-2570 9 mg or 18 mg once daily for the extension period.",[29],"Drug: Placebo",[31,37,41,45],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","D-2570 9mg","Oral D-2570 9 mg administered once daily for 24 weeks during the double-blind treatment period. Eligible subjects may continue the same dose in the 24-week extension period",[9],null,{"type":32,"name":38,"description":39,"armGroupLabels":40,"otherNames":36},"D-2570 18mg","Oral D-2570 18 mg administered once daily for 24 weeks during the double-blind treatment period. Eligible subjects may continue the same dose in the 24-week extension period.",[15],{"type":32,"name":42,"description":43,"armGroupLabels":44,"otherNames":36},"Placebo","Oral placebo administered once daily for 24 weeks during the double-blind treatment period. Subjects will be re-randomized to D-2570 9 mg or 18 mg in the extension period.",[25],{"type":32,"name":46,"description":47,"armGroupLabels":48,"otherNames":36},"D-2570 27mg","Oral D-2570 27 mg administered once daily for 24 weeks during the double-blind treatment period. Subjects will be re-randomized to D-2570 9 mg or 18 mg in the extension period.",[20],[50],{"name":51,"role":52,"phone":53,"phoneExt":36,"email":54},"shilin Sha, project manager","CONTACT","15601826678","shilin.sha@inventisbio.com",[56],{"facility":57,"status":36,"city":58,"state":59,"zip":60,"country":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Huashan Hospital, Fudan University","Shanghai","Shanghai Municipality","201203","China",{"type":63,"coordinates":64},"Point",[65,66],121.45806,31.22222,{"lat":66,"lon":65},[69],{"name":70,"role":52,"phone":53,"phoneExt":36,"email":54},"shilin Sha",{"type":72,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100640606",false,"NCT07625891","A Phase 2 Study of D-2570 in Subjects With Non-Segmental Vitiligo","A Phase 2 Multicenter, Randomized, Parallel-group,Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo","D2570-206","Inclusion Criteria:\n\n* Voluntarily signs informed consent and complies with study procedures.\n* Age 18-65 years, male or female.\n* Clinical diagnosis of non-segmental vitiligo at screening.\n* F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo.\n* Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose.\n\nExclusion Criteria:\n\n* \\- Segmental, mixed vitiligo or other concurrent pigmentary\u002Factive skin disorders interfering with study assessment.\n* Over 33% facial or total vitiligo lesions with leukotrichia.\n* Pregnant or breastfeeding females.\n* Active, latent or inadequately treated tuberculosis infection.\n* Positive HIV, active HBV\u002FHCV infection, or untreated syphilis.\n* Current or history of severe herpes infection.\n* Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment.\n* Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study.\n* Uncontrolled thyroid disease, severe cardiovascular\u002Fcerebrovascular disease or other unstable severe systemic disorders.\n* Severe psychiatric disease, suicidal ideation, or alcohol\u002Fdrug abuse within 6 months.\n* Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia).\n* Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing.\n* Clinically significant abnormal lab results: elevated liver\u002Frenal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts.\n* History of severe drug hypersensitivity or drug-related toxicity.\n* Any condition that may impair protocol compliance or study participation per investigator judgment.","ALL","18 Years","65 Years",{"count":84,"type":85},160,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.\n\nEligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase, where those on 27 mg or placebo will switch to one of the lower doses.\n\nAll participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.",[91,92],"Vitiligo","Non-Segmental Vitiligo (NSV)",[94,95,96],"Non-segmental Vitiligo","D-2570","Phase 2 Clinical Trial","NOT_YET_RECRUITING","2026-05-28",{"date":100,"type":101},"2026-06-04","ACTUAL",{"date":103,"type":85},"2026-05-30",{"date":105,"type":85},"2028-05",{"name":5,"class":6},1]